Expansion of headquarters and laboratories
Emulate inaugurated a new headquarters and laboratory at Drydock Avenue in Seaport District, Boston, in February 2016.
The new facility, located in the existing innovation and design building, will be used as headquarters and for support of commercial activities, product development, and collaborative research programmes for the company’s proprietary organs-on-chips technology.
The proprietary technology helps to predict the potential efficacy and safety of drug candidates, and improves the drug development process.
The facility will accommodate 40 employees and can be expanded for 85 employees in the future. Facility construction began in 2014 and was completed within 18 months. It was opened for commercial operations in February 2016.
The headquarters, located in an eight-storey building, has more than 20,000ft² of total floor space. It is expected to provide the next stage of evolution as Emulate moves towards the industry launch of its proprietary organ-chips within an automated human emulation system.
It is equipped with laboratories to carry out support commercial activities, product development, and collaborative research programmes for the organs-on-chips technology.
The headquarters will facilitate collaboration in Boston’s biotechnology hub of pharmaceutical and biotech companies by offering organs-on-chips technology.
It can be used to establish strategic collaborations to use organs-on-chips technology to develop more effective and safer drugs, consumer products and foods, as well as improve patient wellbeing through new precision medicine and personal health applications.
Organs-on-chips technology, developed by Emulate, is a new automated living human emulation system that knows the inner workings of human biology by providing researchers ways to assess human responses with greater precision and detail.
An organ-chip the size of a USB memory stick made for the lung, liver, brain or kidney, contains tiny hollow channels lined with numerous living human cells and tissues.
It is a living, micro-engineered environment that recreates the natural physiology and mechanical forces that cells experience within the human body.
The lab-ready organic chips, instrumentation and software developed by Emulate will offer a system that supports effective innovation, design and safety of products across a range of industries, including pharmaceuticals, agriculture, cosmetics, chemical-based consumer products and precision medicine.
The company produces a range of products based on the organs-on-chips technology, including lung chip, liver chip, intestine chip, kidney chip and brain chip. The chips are comprised of micro-engineered environments lined with living human cells and tissues.
Local industry collaborators for Emulate include Johnson & Johnson Innovation Centre, Merck and academic researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University.
Based in Boston, Emulate creates living products to understand how diseases, medicines, chemicals and foods affect human health.
The company’s human emulation system sets a new standard for recreating true-to-life human biology, which is being used to advance product innovation, design and safety across various applications, including drug development, agriculture, cosmetics, chemical-based consumer products and personalised health.
Emulate holds an exclusive license from Harvard University to a broad intellectual property portfolio for the organ-chips technology and related systems worldwide.
Taysha Gene Therapies will build a new current Good Manufacturing Practices (cGMP) gene therapy manufacturing facility in Durham, North Carolina,…
Cytiva opened a new facility for manufacturing Xcellerex XDR bioreactors in Shrewsbury, Massachusetts, US, in December 2020. The new manufacturing…
Lonza announced the expansion of its bioconjugation facility at its Visp site in Switzerland in December 2020. The expansion will…
Thermo Fisher Scientific is developing a new current good manufacturing practice (cGMP) facility in Carlsbad, California to expand its clinical…